The serotonin 5-HT1A receptor agonist tandospirone improves executive function in common marmosets

• Published in: Behavioural brain research 2015-07, Vol.287, p.120-126
• Main Authors: Baba, Satoko, Murai, Takeshi, Nakako, Tomokazu, Enomoto, Takeshi, Ono, Michiko, Shimizu, Isao, Ikeda, Kazuhito
• Format: Article
• Language: English
• Subjects: Animals; Antipsychotic; Antipsychotic Agents - pharmacology; Callithrix; Common marmoset; Dopamine Agonists - pharmacology; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive function; Executive Function - drug effects; Executive Function - physiology; Haloperidol - pharmacology; Isoindoles - pharmacology; Male; Object retrieval with detour; Piperazines - pharmacology; Piperidines - pharmacology; Psychological Tests; Psychotropic Drugs - pharmacology; Pyrimidines - pharmacology; Receptor, Serotonin, 5-HT1A - metabolism; Receptors, Dopamine D1 - agonists; Receptors, Dopamine D1 - metabolism; Risperidone - pharmacology; Schizophrenia; Serotonin 5-HT1 Receptor Agonists - pharmacology; Serotonin 5-HT1A receptor
• ISSN: 0166-4328; 1872-7549
• DOI: 10.1016/j.bbr.2015.03.025

•The 5-HT1A receptor agonist tandospirone improved marmosets executive function.•Blonanserin had no detrimental effect on marmoset executive function.•Co-treatment with tandospirone and blonanserin improved marmosets executive function.•Tandospirone given with other antipsychotics did not affect animals’ executive function.•Tandospirone is a promising candidate for the treatment of cognitive impairment. Previous pilot clinical studies have shown that the serotonin 5-HT1A receptor agonist tandospirone has beneficial effect on cognitive deficits associated with schizophrenia. In the present study, we evaluated the cognitive efficacy of tandospirone, given alone or in combination with the antipsychotic blonanserin, risperidone or haloperidol, on executive function in marmosets using the object retrieval with detour (ORD) task. Treatment with tandospirone alone at 20 and 40mg/kg increased the number of correct responses in the difficult trial, while risperidone (0.3mg/kg) and haloperidol (0.3mg/kg) decreased the number of correct responses in this trial. On the other hand, blonanserin (0.1–0.3mg/kg), an atypical antipsychotic highly selective for dopamine D2/D3 and serotonin 5-HT2A receptors, did not affect the number of correct responses in both the easy and difficult trials. Co-treatment with tandospirone (20mg/kg) and risperidone (0.1–0.3mg/kg) or haloperidol (0.1–0.3mg/kg) did not improve animals’ performance in the difficult trial. However, co-treatment with tandospirone and blonanserin (0.1–0.3mg/kg) increased the number of correct responses in the difficult trial. In addition, treatment with the dopamine D1 receptor agonist SKF-81297 at 1mg/kg increased marmosets correct responses in the difficult trial. These results suggest that tandospirone is a promising candidate for the treatment of cognitive deficits associated with schizophrenia and that adjunctive treatment with tandospirone and blonanserin is more appropriate for cognitive deficits than combination therapy with tandospirone and risperidone or haloperidol. The results of this study also indicate that the putative mechanism of action of tandospirone might be related to enhancement of dopamine neurotransmission via activation of the 5-HT1A receptor.